Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Glenmark, Granules shares gain after USFDA developments; check details here
Glenmark Pharmaceuticals and Granules India announced key developments in the US market, including a product launch and a regulatory milestone that strengthen their generics portfolios.
Diamond Power Infrastructure shares jump 10% after Rs 435 crore order for Hyderabad data centre projects
Diamond Power Infrastructure's stock surged after securing a substantial Rs 435 crore order for power cables for Hyderabad's 310 MW data center projects. This significant deal, involving major players like L&T, Sterling & Wilson, and Blue Star, underscores the company's growing prominence in supplying critical infrastructure for India's booming data center segment. The order, one of the largest of its kind, highlights Diamond Power's manufacturing prowess and reliability.
Glenmark launches generic Olanzapine injection in US
Glenmark Pharmaceuticals has launched a generic version of Olanzapine injection in the United States, offering a treatment for schizophrenia and bipolar disorder. This move by its US arm, Glenmark Pharmaceuticals Inc., introduces a bioequivalent alternative to Zyprexa intramuscular injection. The company aims to expand its injectable offerings and bolster its presence in the institutional market, targeting a segment with significant annual sales.
Supriya Lifescience drops after customs probe against senior executive under NDPS Act
Supriya Lifescience declined 5.64% to Rs 923.70 after the company disclosed that judicial proceedings have been initiated against a senior employee by the Special Investigation and Intelligence branch of the Customs Department.
Healthcare stock Unihealth Hospitals hits 5% upper circuit; here's why
Unihealth Hospitals shares hit the 5% upper circuit after announcing a 49.81% stake acquisition in Uganda's Victoria Hospital, boosting its ownership to 99.81%. This strategic move supports its international expansion goals and ensures future economic benefits directly benefit its shareholders.
Chola Securities’ Dharmesh Kant bets on banks, power; cautions on consumer valuations
Dharmesh Kant, Head Research at Chola Securities, says India's growth outlook remains strong, driven by robust demand, infrastructure execution and healthy credit growth. He remains positive on power equipment after further correction, prefers select private and PSU banks, sees value in pharma and hospitals, and is constructive on Mumbai-focused real estate. However, he advises caution on richly valued consumer stocks despite improving business fundamentals.
Glenmark Pharma gains as US arm launches generic Olanzapine injection
Glenmark Pharmaceuticals rose 1.13% to Rs 2,234.90 after its subsidiary, Glenmark Pharmaceuticals Inc., USA, has launched Olanzapine for Injection, 10 mg/vial, Single-Dose Vial in the United States.
Granules India secures FTF status for Sodium Oxybate ER for Oral Suspension ANDA
Granules India announced that it has secured Sole First-to-File (FTF) status for its Abbreviated New Drug Application (ANDA) for Sodium Oxybate Extended-Release for Oral Suspension, the generic equivalent of LUMRYZ extended-release oral suspension.
Poly Medicure among 4 stocks that closed below VWAP
Four Nifty500 stocks, Poly Medicure, Aditya Birla Real Estate, Siemens Energy India, and Onesource Specialty Pharma, closed over 2% below their VWAP on July 3, indicating potential bearish momentum and heightened selling pressure, according to technical scan data.
Stocks to buy or sell: Dharmesh Shah of ICICI Sec suggests buying Shriram Finance, Piramal Pharma shares on 6 July
Indian benchmark indices, Sensex and Nifty 50, opened higher on July 6, driven by gains in private banking stocks following strong quarterly updates from HDFC Bank and Axis Bank. Market breadth was positive with 14 of the 16 major indices in the green.
Glenmark USA launches Olanzapine for Injection
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. Glenmark's Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa2 IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253].
Fermenta Biotech receives FSSAI approval for its Vitamin D3 (Cholecalciferol) - Plant Source
For use as ingredient in Health Supplements, Nutraceuticals and Food Products